Johnson & JohnsonJNJ
JNJ
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
142% more first-time investments, than exits
New positions opened: 419 | Existing positions closed: 173
25% more call options, than puts
Call options by funds: $2.64B | Put options by funds: $2.11B
4% more funds holding
Funds holding: 3,826 [Q3] → 3,984 (+158) [Q4]
0.32% more ownership
Funds ownership: 71.58% [Q3] → 71.9% (+0.32%) [Q4]
8% less capital invested
Capital invested by funds: $280B [Q3] → $258B (-$21.9B) [Q4]
24% less funds holding in top 10
Funds holding in top 10: 189 [Q3] → 144 (-45) [Q4]
31% less repeat investments, than reductions
Existing positions increased: 1,322 | Existing positions reduced: 1,905
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$152
7%
downside
Avg. target
$165
1%
upside
High target
$181
11%
upside
8 analyst ratings
3 positive
38%
5 neutral
63%
0 negative
0%
B of A Securities Tim Anderson 46% 1-year accuracy 6 / 13 met price target | 5%upside $171 | Neutral Maintained | 5 Mar 2025 |
RBC Capital Shagun Singh 61% 1-year accuracy 41 / 67 met price target | 11%upside $181 | Outperform Reiterated | 19 Feb 2025 |
Barclays Matt Miksic 63% 1-year accuracy 26 / 41 met price target | 2%upside $166 | Equal-Weight Maintained | 28 Jan 2025 |
Morgan Stanley Terence Flynn 42% 1-year accuracy 8 / 19 met price target | 0%upside $163 | Equal-Weight Maintained | 23 Jan 2025 |
Stifel Rick Wise 46% 1-year accuracy 16 / 35 met price target | 5%downside $155 | Hold Maintained | 23 Jan 2025 |
Financial journalist opinion
Based on 52 articles about JNJ published over the past 30 days
Neutral
24/7 Wall Street
1 day ago
Forget About a Market Correction: Baby Boomers Should Buy These 3 Bulletproof Dividend Stocks Now
Market volatility can be unsettling for any investor.
Neutral
Reuters
1 day ago
Lilly, J&J boosted spending on executive security after UnitedHealth shooting
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, with both citing increased threats after a UnitedHealth insurance executive was murdered outside the company's investor meeting in December, regulatory filings show.
Neutral
Business Wire
1 day ago
Six Dean Omar Branham Shirley Attorneys Honored for Representation of Plaintiffs
DALLAS--(BUSINESS WIRE)--Leading plaintiff trial firm Dean Omar Branham Shirley, LLP is pleased to announce the selection of partners Jessica Dean, Amin Omar, Trey Branham, Lisa Shirley, Ben Braly and attorney Mark Linder to the list of Lawdragon's 500 Leading Plaintiff Consumer Lawyers for 2025. The annual listing describes this year's honorees as “coast-to-coast champions who dedicate their lives to helping people going through the hardest moments of their lives.” “A special thank you to Lawd.
Positive
Finbold
1 day ago
ChatGPT picks 3 safe haven stocks to buy for 2025
The advent of artificial intelligence (AI) and machine learning has, in many ways, revolutionized the financial markets.
Neutral
Zacks Investment Research
1 day ago
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Neutral
CNBC Television
2 days ago
Cramer's Mad Dash: Johnson & Johnson
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
Positive
24/7 Wall Street
3 days ago
3 Dividend Stocks Set to Provide Stability in Market Chaos
Investors were in growth mode in the last two years as the stock market delivered blockbuster returns.
Positive
Benzinga
3 days ago
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Neutral
PRNewsWire
3 days ago
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study Clinical response and remission rates continued to improve through Week 28, building on strong data recently reported for the plaque psoriasis Phase 3 program Icotrokinra demonstrates potential to offer therapeutic benefit and tolerability with a once daily oral treatment SPRING HOUSE, Pa. , March 10, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra (JNJ-2113), the first investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC).
Neutral
PRNewsWire
5 days ago
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline results from Phase 3 ICONIC-ADVANCE 1&2 studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO These results pave the way to initiate the first-ever head-to-head study seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe plaque PsO SPRING HOUSE, Pa. , March 8, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis (PsO) seeking to demonstrate the superiority of an oral pill, icotrokinra, compared to an injectable biologic, ustekinumab.
Charts implemented using Lightweight Charts™